Response to erenumab assessed by Headache Impact Test-6 is modulated by genetic factors and arterial hypertension: An explorative cohort study.
Chiara ZeccaSalvatore TerrazzinoDavide ParaGiovanna CampagnaMichele VianaChristoph J SchankinClaudio GobbiPublished in: European journal of neurology (2023)
Response to ERE was associated with comorbid hypertension and specific allelic variants in CALCRL and RAMP1 genes. Results require confirmation in future studies.